Catalyst Funds Management’s ClearPoint Neuro CLPT Stock Holding History

Catalyst Funds Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,175	Closed	-$169K	–	486
2025 Q1	$169K	Buy	+14,175	New	+$220K	0.04%	358
2024 Q4	–	Sell	-4,400	Closed	-$49.3K	–	514
2024 Q3	$49.3K	Hold	4,400	–	–	0.01%	798
2024 Q2	$23.7K	Buy	+4,400	New	+$25.5K	0.01%	629

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Catalyst Funds Management's CLPT Position: Q2 2025 in Review

Catalyst Funds Management sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 14,175 shares — an estimated $169K sold.

Catalyst Funds Management first reported a position in CLPT in Q2 2024 and held it in 3 quarters. The position peaked at $169K in Q1 2025. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

Catalyst Funds Management reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
Catalyst Funds Management sold 14,175 ClearPoint Neuro shares in Q2 2025, an estimated $169K.
Catalyst Funds Management first reported a position in ClearPoint Neuro in Q2 2024 and held it in 3 quarters.
Catalyst Funds Management's ClearPoint Neuro position peaked at $169K in Q1 2025.
96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.